NLM Digital Collections

Search

Start Over Subjects Drug Approval ✖Remove constraint Subjects: Drug Approval Subjects Endpoint Determination ✖Remove constraint Subjects: Endpoint Determination Titles Hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment ✖Remove constraint Titles: Hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment

Refine by:

more »

  • Hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment1